Table 3 Demografic according to surgical technique

Age, years (Median, range)

70,5 (61–67)

67 (42–81)

0,567

Sex (M/F) n(%)

7 (63,6)/4(36,4)

6(46,2)/7(53,8)

0,444

ASA n(%)

0,754

 I

1(9)

2(16)

 II

7(63,6)

8(61)

 III

3(27,3)

3 (23)

BMI

24.1 (21,1–29)

26.4 (22,3–28,1)

0,456

Lesion number n(%)

3,2(1–10)

2,1 (1–7)

0,150

Tumor size mm (bigger lesion) (Median, range)

72 (15–120)

59 (35–180)

0,287

Number of hepatic segment interest n(%)

3 (2–6)

2 (1–6)

0,232

Neoadjuvant chemotheraty n(%)

 yes

7(63,6)

7(53,8)

0,855

 no

4 (36,4)

6(46,2)

Enlapse time between stage /PVE and mayor hepatectomy. Days (Median, range)

13,9 (7–22)

66 (36–106)

 < 0,01

KGR (%/day)

2,8

0,4

 < 0,01

Hepatectomy n(%)

0,101

 Extended RH

6(54)

7(54)

 Extended LH

1(9)

1(8)

 RH

0

5(38)

 RH + metastasect

2(18)

0

 Extended RH + metastasectomy

1(9)

0

 Extended LH + metastasectomy

1(9)

0

Associated biliary resection n (%)

 yes

2(18,2)

4(30)

0,356

 no

9(81,8)

9(70)

Caval resection

0,213

 no

11(100)

11(84)

 Resection

0

1(8)

 Trombectomy

0

1(8)

Histology type n(%)

 IHCC

3(27,3)

4(30)

0,318

 Hepatocarcinoma

0

2(16)

 Metastasis

8(72,7)

6(46)

 Other

0

1(8)

Intraoperative trasfusione, ml (Median, range)

450 (0–600)

300 (0–800)

0,564

Hospital stay, days (median, range)

22 (6–90)

7,9 (6–35)

0,101

Dindo Clavien > III n (%)

 yes

2(18)

4(30)

0,431

 no

9(72)

9(70)

PHLF

0,989

 no

6(55)

8(61)

 A

2(18)

2(16)

 B

2(18)

2(16)

 c

1(9)

1(8)

30 Day Mortality

0,692

 yes

1(9)

1(8)

 no

10(91)

12(92)

90 Day Mortality

0,222

 yes

2(22)

1(8)

 no

9(78)

12(92)